27.74

3.61% -1.04

Arcutis Biotherapeutics Inc (ARQT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ARQT? Forum Prognose

Schlusskurs vom Vortag:

$28.78

Offen:

$28.66

24-Stunden-Volumen:

1.57M

Relative Volume:

0.92

Marktkapitalisierung:

$3.47B

Einnahmen:

$415.62M

Nettoeinkommen (Verlust:

$-2.38M

KGV:

-976.76

EPS:

-0.0284

Netto-Cashflow:

$16.92M

1W Leistung:

+7.48%

1M Leistung:

+19.41%

6M Leistung:

-1.70%

1J Leistung:

+81.66%

1-Tages-Spanne:

$26.96

$28.98

1-Wochen-Bereich:

$25.25

$29.84

52-Wochen-Spanne:

$13.70

$31.77

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Firmenname

Arcutis Biotherapeutics Inc

Sektor

Healthcare (1096)

Branche

Biotechnology (616)

Telefon

805-418-5006

Adresse

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Mitarbeiter

354

Twitter

@ArcutisBio

Nächster Verdiensttermin

2026-08-05

Neueste SEC-Einreichungen

ARQT's Discussions on Twitter

Compare ARQT vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARQT Arcutis Biotherapeutics Inc	27.74	3.47B	415.62M	-2.38M	16.92M	-0.0284
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-25	Eingeleitet	Goldman	Neutral
2024-12-30	Eingeleitet	H.C. Wainwright	Buy
2024-08-28	Eingeleitet	Jefferies	Buy
2024-01-03	Hochstufung	Mizuho	Neutral → Buy
2023-10-26	Herabstufung	Mizuho	Buy → Neutral
2023-10-13	Herabstufung	Goldman	Buy → Neutral
2022-09-07	Eingeleitet	Needham	Buy
2022-03-17	Eingeleitet	Goldman	Buy
2021-06-30	Eingeleitet	Mizuho	Buy
2021-05-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-11-09	Hochstufung	Goldman	Neutral → Buy
2020-10-08	Eingeleitet	Truist	Buy
2020-02-25	Eingeleitet	Cantor Fitzgerald	Overweight
2020-02-25	Eingeleitet	Cowen	Outperform
2020-02-25	Eingeleitet	Goldman	Neutral
2020-02-25	Eingeleitet	Guggenheim	Buy

Alle ansehen

Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten

Jul 11, 2026

Understanding Momentum Shifts in (ARQT) - Stock Traders Daily

Jul 11, 2026

Jul 08, 2026

Could Arcutis (ARQT) Infant Label Bid Clarify the Limits of Its Single-Drug Strategy? - simplywall.st

Jul 08, 2026

BREAKING: US FDA Sets PDUFA for Roflumilast Cream 0.05% in Infants With AD - The Dermatology Digest

Jul 08, 2026

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo

Jul 08, 2026

Arcutis gets FDA review for Zoryve 0.05% label expansion (ARQT) - Seeking Alpha

Jul 08, 2026

Arcutis Biotherapeutics (ARQT) Receives FDA Acceptance for Zoryve Cream - GuruFocus

Jul 08, 2026

FDA accepts Arcutis application for infant eczema treatment - Investing.com

Jul 08, 2026

Arcutis: FDA to Review Zoryve for Atopic Dermatitis in Infants - Moomoo

Jul 08, 2026

FDA accepts Arcutis application for infant eczema treatment By Investing.com - Investing.com India

Jul 08, 2026

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - The Manila Times

Jul 08, 2026

FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (Roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - Moomoo

Jul 08, 2026

Jul 07, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 07, 2026

Arcutis Biotherapeutics (ARQT) Rises 4.6% as Biotech Sector Momentum Drives Shares HigherResistance Breakout Stocks - dars.gov.et

Jul 07, 2026

Jul 05, 2026

Price to sales forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView

Jul 05, 2026

Jul 04, 2026

3 Healthcare Stocks Built For Higher Rates And Steady Demand - Sahm

Jul 04, 2026

Jul 03, 2026

Arcutis Biotherapeutics (ARQT) Edges Lower, Tests Key Support Levels Amid ConsolidationEquity Put Call - dars.gov.et

Jul 03, 2026

Comparative Analysis of Arcutis and Vertex Biotherapeutics - Intellectia AI

Jul 03, 2026

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? - The Motley Fool

Jul 03, 2026

Jul 02, 2026

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 02, 2026

Arcutis lures 9 new hires with 61,000 stock awards - Stock Titan

Jul 02, 2026

Jul 01, 2026

Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo

Jul 01, 2026

Jun 30, 2026

Arcutis launches virtual dermatology platform for skin conditions By Investing.com - Investing.com India

Jun 30, 2026

Arcutis Launches Virtual Dermatology Platform to Boost Access to Roflumilast - The Dermatology Digest

Jun 30, 2026

Avoiding Lag: Real-Time Signals in (ARQT) Movement - Stock Traders Daily

Jun 30, 2026

Arcutis launches virtual dermatology platform for skin conditions - Investing.com

Jun 30, 2026

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications - The Manila Times

Jun 30, 2026

Arcutis’ new virtual dermatology platform targets care gaps for 45M Americans - Stock Titan

Jun 30, 2026

FDA approves Zoryve cream for plaque psoriasis in children age 2+ - Investing.com India

Jun 30, 2026

FDA approves Zoryve cream for plaque psoriasis in children age 2+ By Investing.com - Investing.com India

Jun 30, 2026

Jun 29, 2026

Arcutis Biotherapeutics stock edges lower with bullish trend intact after once-daily cream approval - Traders Union

Jun 29, 2026

Arcutis Biotherapeutics (ARQT) Secures FDA Approval for ZORYVE C - GuruFocus

Jun 29, 2026

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 - The Manila Times

Jun 29, 2026

Arcutis Biotherapeutics Announces FDA Approval of Expanded ZORYVE Cream 0.3% Indication for Children With Plaque Psoriasis Down to Age 2 - Quiver Quantitative

Jun 29, 2026

FDA broadens Arcutis’ ZORYVE to children as young as 2 - Stock Titan

Jun 29, 2026

Jun 28, 2026

Arcutis Biotherapeutics (ARQT) Edges Higher as Bullish Momentum BuildsBreakout Trade - dars.gov.et

Jun 28, 2026

Jun 26, 2026

A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36 - Moomoo

Jun 26, 2026

Jun 25, 2026

Arcutis Biotherapeutics Inc Actuals & Estimates (NASDAQ:ARQT) - TradingView

Jun 25, 2026

ARQT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 23, 2026

Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% - The Globe and Mail

Jun 23, 2026

Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% - The Motley Fool

Jun 23, 2026

Jun 22, 2026

Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price - ChartMill

Jun 22, 2026

Jun 19, 2026

Discipline and Rules-Based Execution in ARQT Response - Stock Traders Daily

Jun 19, 2026

Arcutis Biotherapeutics (ARQT) Holds Steady Near Support as Investors Eye ResistanceBearish Pattern Stocks - dars.gov.et

Jun 19, 2026

Jun 18, 2026

ARQT News | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill

Jun 18, 2026

Arcutis director Sue-Jean Lin sells $120,586 in company shares By Investing.com - Investing.com Australia

Jun 18, 2026

Arcutis (ARQT) director trades shares under Rule 10b5-1 stock plan - Stock Titan

Jun 17, 2026